title: Treatment patterns and outcomes in bulky stage IB2 cervical cancer patients: a single institution's experience over 14 years.
abstract: OBJECTIVE
  The aim of this study was to assess various treatment options in stage IB2 cervical cancer patients.
  
  
  METHODS
  Between January 1995 and May 2007, 63 patients with stage IB2 were treated by radical hysterectomy (n = 28), primary concurrent chemoradiation (CCRT, n = 16) or radiation therapy (RT, n = 19). Disease-free survival (DFS) and overall survival (OS) were compared between these treatment modalities.
  
  
  RESULTS
  The 3-year DFS of the surgical approach group was 67.5% compared to 70.3% of the primary RT/CCRT group (p = 0.603). The 5-year OS of all patients was 75.9%. The 5-year OS of the surgical approach group was 81.6% compared to 76.2% of the primary RT/CCRT group (p = 0.578). Twelve (42.8%) of 28 surgically treated patients had high-risk pathologic factors. Out of 20 premenopausal patients who underwent the surgical approach, ovarian preservation was possible in 13 patients without adjuvant CCRT. Of these 13 patients, 7 patients did not experience disease recurrence and continued normal ovarian function.
  
  
  CONCLUSIONS
  Both radical hysterectomy and primary RT/CCRT are effective treatment options in IB2 cervical cancer. In addition, the surgical approach can be considered for preserving ovarian function in premenopausal IB2 cervical cancer patients.
authors.affiliation: Departments of Obstetrics and Gynecology, Ajou University Hospital, Suwon, Korea.
authors.forename: Woo Young
authors.initials: WY
authors.lastname: Kim
authors.forename: Suk-Joon
authors.initials: SJ
authors.lastname: Chang
authors.forename: Ki-Hong
authors.initials: KH
authors.lastname: Chang
authors.forename: Seung-Chul
authors.initials: SC
authors.lastname: Yoo
authors.forename: Mison
authors.initials: M
authors.lastname: Chun
authors.forename: Hee-Sug
authors.initials: HS
authors.lastname: Ryu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010053:Ovary / Q000502:physiology; D011878:Radiotherapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents